Navigation Links
Nasseo’s TiArray™ Dental Implant System Receives FDA Approval

San Diego, CA (PRWEB) September 16, 2013

Nasseo, Inc. announced today that the U.S. Food and Drug Administration (“FDA”) has approved its TiArray™ Dental Implant System for commercial sale in the U.S. It is the first commercial application of Nasseo’s proprietary surface modification technology, which was initially developed over 8 years out of UC San Diego Bioengineering and Materials Science Departments, and the Bio-Implant Laboratory at Lund University in Sweden. The inflammation (“peri-implantitis”) that many patients suffer in reaction to existing dental implants is currently a significant cause of both bone loss and dental implant failure over time. Patients and doctors alike are seeking better performing implants which lower inflammation and promote faster healing.

The TiArray™ Dental Implant System was developed to address a gap in medical care that is currently adding significant costs to the US healthcare system: the failure of dental implants. The $1B+ US dental implant market is growing quickly as clinicians move away from dentures and bridges. However, existing dental implants often fail, requiring repeated clinical visits and additional implants, which is expensive for patients and an inefficient use of clinician time. Due to high dental implant failure rates and growing peri-implantitis concerns, certain high-risk patient populations (e.g. heavy smokers) are being advised against implants altogether. Nasseo aims to address these concerns and provide a longer lasting dental implant.

Dr. Garrett Cale Smith, Co-Founder and CEO, says “Achieving the significant milestone of FDA approval allows us to continue to increase the value of our technology by running clinical trials with key opinion leaders at leading centers. The FDA approval of the Nasseo TiArray™ Dental Implant System is an important step toward our goal of providing dentists and millions of patients worldwide with improved treatment options.”

While the company’s FDA approval news will accelerate its timeline for clinical trials and commercialization, Nasseo is excited to attend two prominent investor and partnership conferences later this month. Dr. Smith will present the company’s work at the Rocky Mountain Life Sciences Investor & Partnership Conference taking place September 18-19 at The Ritz-Carlton in Denver, while Kayvon Pourmirzaie, Co-Founder and COO, will represent Nasseo at the NCET2 Global 1000 Corporate Venturing Conference on September 17-18 at the Marriott San Mateo. Nasseo is seeking to close on a Series A investment/corporate partnership round by the Fall 2013.

Pourmirzaie says, “Our success so far has been based not only upon our novel technology, but also the enthusiastic support of the scientific and business communities. We will continue to evaluate new strategic partnerships that support our efforts to conduct clinically relevant studies and bring Nasseo’s highly differentiated TiArray™ Dental Implant System to market.

For more information about Nasseo’s surface modification technology, the TiArray™ Dental Implant System, investment opportunities, or to request meetings at the events listed above, please contact Kayvon Pourmirzaie at kayvon(at)nasseo(dot)com.

About the Dental Implant Market
In the United States, over 70% of adults have lost at least one permanent tooth, while 25% of American adults over 65 have lost all of their teeth. This demand amounts to a fast growing $1B+ US market. However, existing implants on the market experience high failure rates and peri-implantitis issues depending upon the tooth’s location and other factors and are not recommended for a number of large populations including diabetics, heavy smokers, and patients with gum disease. The demand for dental implants is expected to double over the next five years.

About Nasseo, Inc.
Nasseo, Inc. is a medical device company using state of the art surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants. Nasseo is a member of the BioInspire™ medical incubator and is a CONNECT Portfolio company. The Company has won many competitions including the Arizona Innovation Challenge $250K grant, the 2013 CONNECT Life Sciences Capital Competition, and the 2012 UCSD Entrepreneur Challenge, and has been selected to the 2012 World’s Best Technology (WBT) Innovation Marketplace and the 2013 TechConnect World/National Innovation Showcase. Nasseo is based in Phoenix, AZ and San Diego, CA. Please visit for more information.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Accidental nanoparticle discovery could hail revolution in manufacturing
2. Local Dentist is Saving Lives with His Cutting-edge Approach to Dental Caries
3. Crisafulli Dental Launches Ground Breaking Cavity Prevention Program That Can Lower Decay Rates by 74%
4. RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants
5. Local Dentist is Saving Lives with Her Cutting-edge Approach to Dental Caries
6. Brookfield Dental Care Launches Ground-breaking Cavity Prevention Program That Can Lower Decay Rates by 74%
7. Preserve Your Smile Dental is Saving Lives with a Cutting-Edge Approach to Dental Caries
8. Miami Dentist is Saving Lives with His Cutting-Edge Approach to Dental Caries
9. Waterloo Heights, a Neighborhood Smiles Dental Practice is Taking a Bold New Approach to the Cavity Epidemic
10. Electronic Headband That Detects and Treats Addictive In-Sleep Behavior to be Demonstrated at Annual Holistic Dental Conference by Holistic Technologies
11. Local Dentist is Saving Lives with His Cutting-Edge Approach to Dental Caries
Post Your Comments:
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... While ... machines such as the Cary 5000 and the 6000i models are higher end machines ... is the height of the spectrophotometer’s light beam from the bottom of the cuvette ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):